• MLN8237 (Alisertib): A Translational Aurora A Strategy

  2026-09-21

  Aurora kinase A is emerging as a mechanistically grounded vulnerability in aggressive cancers, including retinoblastoma. This thought-leadership article connects the biology of AURKA–MYCN signaling with the selective pharmacology of MLN8237 (Alisertib), outlining practical workflows, translational safeguards, and the evidence needed to move from target expression to actionable response.

• DNA Frameworks Improve Enzymatic Oligonucleotide Synthesis

  2026-09-21

  Li and colleagues developed a tetrahedral DNA nanostructure interface that organizes primers for more accessible enzymatic oligonucleotide synthesis. The framework improved substrate interaction, reaction kinetics, sequence yield, and information recovery, while also defining important limits for translating the approach to fluorescent DNA-labeling workflows.

• Nigericin Sodium Salt: Protocol and QC Guide

  2026-09-20

  Nigericin sodium salt is a potassium ionophore for controlled studies of K+/H+ exchange, membrane ion gradients, cytoplasmic pH regulation, and related assay readouts. This guide covers preparation, controls, and failure analysis for research workflows; it should not be used for diagnosis, treatment, or unvalidated clinical applications.

• Metal-Ion Enrichment Improves mRNA Vaccine Design

  2026-09-19

  The reference study introduces a manganese-mediated condensation strategy that creates a dense mRNA core before lipid coating, increasing payload loading and cellular uptake relative to conventional LNP-mRNA formulations. Its findings support a dose-sparing vaccine design principle, while also highlighting the need to validate metal-ion composition, lipid architecture, immune effects, and mRNA chemistry across models.

• ZCL278: A Selective Cdc42 Inhibitor Workflow

  2026-09-18

  ZCL278 enables time-resolved control of Cdc42 signaling in motility, neuronal morphology, and fibroblast assays. This practical guide connects target-engagement measurements with imaging and viability endpoints while separating established product evidence from exploratory fibrosis applications.

• Polybrene: Designing Cleaner p53 Reactivation Assays

  2026-09-18

  Polybrene and Hexadimethrine Bromide can improve gene-delivery consistency, but their greatest value in mutant-p53 research lies in controlling assay variability. This article connects Polybrene-mediated delivery design with the chemically induced proximity mechanism reported for TRAP-1, while separating delivery effects from genuine p53 reactivation.

• Simvastatin (Zocor) Research Workflows

  2026-09-17

  Build reproducible Simvastatin (Zocor) workflows for lipid metabolism, hepatic cancer, and hyperlipidemia models. This guide connects formulation control with apoptosis, lipid-accumulation, and lipidomics readouts while highlighting practical troubleshooting decisions.

• HIV-1 Signalling and Nuclear Pore Remodelling

  2026-09-17

  The reference study identifies nuclear import through the nuclear pore complex as a decisive barrier to HIV-1 infection of resting CD4+ T cells. It shows that cell–cell spread activates CD4–LCK–CDK1 signalling, remodels nucleoporins, and licenses capsid entry into the nucleus without requiring conventional cell-cycle entry.

• Deferasirox Review: Evidence for Oral Iron Chelation

  2026-09-16

  This formulary review established deferasirox as an oral tridentate chelator and evaluated its pharmacology, comparative efficacy, tolerability, adherence implications, and economic context. Its central practical finding was that oral treatment could provide a clinically meaningful alternative to demanding deferoxamine infusions for transfusion-related iron overload, while safety and organ-specific iron mobilization remained important considerations.

• Oteseconazole (VT-1161) Assay Guide

  2026-09-16

  A scenario-based laboratory guide to using Oteseconazole (VT-1161), SKU BA1665, in Candida susceptibility, viability, and cytotoxicity workflows. It connects CYP51 mechanism, concentration selection, solvent controls, resistance-aware interpretation, and practical product-selection criteria to improve assay clarity.

• 2',7'-Dichlorofluorescein diacetate for ROS Assays

  2026-09-15

  Build more reproducible intracellular ROS measurements with a practical workflow for cancer, toxicology, and drug-discovery studies. The guide also shows how to use this general redox indicator to interrogate ROS-responsive nanocarriers without overinterpreting DCF fluorescence as a species-specific measurement.

• JNJ-26481585: From HDAC Activity to Assay Insight

  2026-09-15

  JNJ-26481585 (Quisinostat) is examined here as an epigenetic modulator for connecting HDAC inhibition with TRIM21–ERK1/2 biology in pituitary adenoma research. The article emphasizes mechanistic assay design, orthogonal readouts, and the limits of translating drug-screening observations into causal claims.

• GSK 2837808A for Reliable LDHA Assays

  2026-09-14

  A scenario-driven guide to using GSK 2837808A (SKU B4929) in viability, glycolysis, lactate, and glucose-consumption experiments. It separates validated LDHA evidence from hypothesis-generating colorectal cancer applications and provides practical guidance on formulation, controls, interpretation, and vendor selection.

• Deuterated Tetrazole CYP51 Inhibitor: V23 Findings

  2026-09-14

  The 2025 European Journal of Medicinal Chemistry study describes V23, a deuterated tetrazole CYP51 inhibitor designed to improve fungal selectivity, metabolic stability, and activity against resistant fungi. V23 combined broad in vitro antifungal activity, effects on fungal phase transformation and biofilms, low apparent cytotoxicity in tested cell lines, and significant in vivo efficacy, although its translational scope remains to be established.

• Clinically Safe Drugs and CRISPR Repair Choice

  2026-09-13

  This study screened 7,240 clinically relevant drug conditions in human induced pluripotent stem cells to identify compounds that redirect CRISPR-induced double-strand break repair toward NHEJ, MMEJ, or HDR. Its findings connect pharmacological perturbation with ESR2, AOX1, ATM, and 53BP1 biology, while highlighting drug combinations with potential synthetic-lethal effects.

8480 records 1/566 page Next 12345 下5页 Last page